RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Irinotecan (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Ipsen; Merrimack Pharmaceuticals
- 22 Dec 2017 Planned number of patients changed from 482 to 486.
- 22 Dec 2017 Planned End Date changed from 1 Sep 2023 to 1 Dec 2021.
- 22 Dec 2017 Planned primary completion date changed from 1 Mar 2022 to 1 Sep 2021.